PET IMAGING AGENTS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)
The global PET imaging agents market is estimated to be valued at USD 3,236.4 Mn in 2026 and is expected to reach USD 6,529.5 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 10.5% from 2026 to 2033. Positron emission tomography (PET) imaging agents (radiotracers or radiopharmaceuticals) are specific chemical compounds labeled with positron-emitting radionuclides that permit non-invasive visualization of metabolic and physiological processes at the molecular scale. PET imaging agents are widely used in oncology, neurology, and cardiology. Major agents include Fluorodeoxyglucose (FDG), Florbetapir, and Flutemetamol, as well as novel amyloid- and tau-targeting tracers, for detection and characterization of diseases.
The global market for PET imaging agents includes the development, production, and distribution of these compounds and is growing as a consequence of advances in radiochemistry, the increasing burden of cancer and neurological disorders, and improved access to molecular imaging. The increasing adoption of precision medicine and personalized diagnostics is also increasing the role of PET imaging agents in clinical decision-making and providing opportunities for pharmaceutical companies, research organizations and healthcare providers.
Market Dynamics
The global PET imaging agents market is driven by the increasing burden of cancer and neurodegenerative disorders, rising demand for accurate detection of disease, and growing clinical application of oncology and neurological radiotracers. The market is also growing due to regulatory approvals of novel PET agents, investments in infrastructure of nuclear medicine, and increasing adoption of PET/Computed Tomography and PET/Magnetic Resonance Imaging, which are improving diagnostic capabilities and clinical applications.
However, a number of constraints are present in the market, such as short radionuclide half-lives pose challenges in terms of production, transportation and supply-chain, while high costs of radiopharmaceutical manufacturing, cyclotron facilities and PET scanners limit access in resource-constrained regions. Nevertheless, next-generation targeted tracers, including prostate-specific membrane antigen and fibroblast activation protein inhibitor agents, alongside the increasing use of theranostics and expansion of nuclear medicine infrastructure across Asia-Pacific, Latin America and the Middle East will offer opportunities within global PET imaging agents market.
Key Features of the Study
Market Segmentation
Table of Contents
*Browse 32 market data tables and 28 figures on ‘PET Imaging Agents Market' - Global forecast to 2033
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
